Sierra Oncology Inc (SRRA) KOL Panel Highlights Momelotinib’s Efficacy - H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating and $29.00 price target on Sierra Oncology Inc (NASDAQ: SRRA) after the company hosted a KOL conference call to discuss in further detail a recent retrospective analysis of its SIMPLIFY-1 and SIMPLIFY-2 programs presented at EHA. The call featured a panel of physicians and scientists in the hematologic malignancy space that highlighted momelotinib’s (MMB) safety, unique MoA, and differentiated efficacy profile in myelofibrosis (MF). Key takeaways were that MMB administration:
1) improved transfusion independence (TI) response rates compared to ruxolitinib randomized patients
2) predicted improved survival rates in those participants with a TI response
3) increased the observed TI rates in MMB administered patients irrespective of baseline anemia severity, platelet count, or transfusion status

The analyst stated "The latest results from EHA are particularly noteworthy, in our opinion, because they identified important factors that impact trial endpoints and overall survival. We believe these links between MMB therapy and successfully treating MF by mitigating anemia are integral for building the case for MMB's adoption in the front-line setting, in combination with other anti-hematolgic malignancy agents, and/or in the overall clinical management of patients with MF."

For an analyst ratings summary and ratings history on Sierra Oncology Inc click here. For more ratings news on Sierra Oncology Inc click here.

Shares of Sierra Oncology Inc closed at $18.14 yesterday.

You May Also Be Interested In

• Stifel Upgrades Barry Callebaut AG (BARN:SW) (BYCBF) to Buy
• Zoetis Inc. (ZTS) PT Lowered to $195 at Piper Sandler
• Carl Zeiss Meditec AG (AFX:GR) (CZMWY) PT Lowered to EUR115 at HSBC